SLC38A2 and cancer: We tested the effect of CB6644 (targeting RUVBL1/2 complex), MKT077 (inhibiting HSPA9), selinexor (blocking XPO1, nuclear exportin), and MeAIB (targeting SLC38A2) on cell lines representing three different cancer types versus the normal fibroblasts.